Pipeline Update: Here’s What to Expect From DermBiont in 2024
DermBiont has completed enrollment in a Phase 2b clinical trial of SM-020 gel 1.0% for the treatment of seborrheic keratoses. “We are pleased to have completed enrollment in our CT-213 clinical trial evaluating SM-020 gel 1.0% for the treatment of SK lesions, the most common benign tumors of the skin,” shares Karl Beutner, M.D., Ph.D., CEO, […]